ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1...
Quatre Lab, una empresa vasca especializada en servicios de Control de Calidad para terapias avanzadas y respaldada por Columbus Venture Partners, lidera un sindicato de inversores que incluye a Accor...
The investors behind QUATRE LAB include Columbus Venture Partners through its Columbus Life Sciences Fund III and Gestión de Capital Riesgo del País Vasco, SGEIC, S.A. – Grupo SPRI, through its ma...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing...
Columbus Life Sciences Fund IV has been recently incorporated and accepted by the CNMV. CVP's fund IV will have a size of EUR 150 million and will follow the same strategy as the previous funds. 10 - ...
Cocoon Bioscience’s funding round, led by Columbus Venture Partners and Cleon Capital, will also include several blue-chip co-investors including the Spanish listed company Viscofan, US-based North ...
Minoryx is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chies...
The shareholders of Algenex, a privately held biotechnology company backed by a group of families advised by Cleon Capital and leading Spanish biotech fund Columbus Venture Partners, today announced a...
Integra Therapeutics, a biotechnology company that creates next generation gene writing tools, has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. T...
Damià Tormo, Managing Partner de Columbus Venture Partners: “El equipo de Sanifit ha conseguido llevar un proyecto de investigación desde la investigación básica de la Universidad de Islas Balea...
Columbus Venture Partners ha apoyado a la compañía desde la serie B, a través de su fondo Columbus INNVIERTE Life Science FCR, así como en la serie «pre OPS» que tuvo lugar en marzo de 2021 y en...